Development of novel pyridazinone-based adenosine receptor ligands.

[1]  A. Cavalli,et al.  The 1,2,4-Triazolo[4,3-a]pyrazin-3-one as a Versatile Scaffold for the Design of Potent Adenosine Human Receptor Antagonists. Structural Investigations to Target the A2A Receptor Subtype. , 2017, Journal of medicinal chemistry.

[2]  Arthur Christopoulos,et al.  Structure of the Adenosine A1 Receptor Reveals the Basis for Subtype Selectivity , 2017, Cell.

[3]  F. Pedata,et al.  Imidazo[1,2-a]pyrazin-8-amine core for the design of new adenosine receptor antagonists: Structural exploration to target the A3 and A2A subtypes. , 2017, European journal of medicinal chemistry.

[4]  K. Varani,et al.  Design, Synthesis, and Pharmacological Characterization of 2-(2-Furanyl)thiazolo[5,4-d]pyrimidine-5,7-diamine Derivatives: New Highly Potent A2A Adenosine Receptor Inverse Agonists with Antinociceptive Activity. , 2016, Journal of medicinal chemistry.

[5]  S. Moro,et al.  Structural refinement of pyrazolo[4,3-d]pyrimidine derivatives to obtain highly potent and selective antagonists for the human A3 adenosine receptor. , 2016, European journal of medicinal chemistry.

[6]  M. Trincavelli,et al.  Further studies on pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones as potent and selective human A1 adenosine receptor antagonists. , 2015, European journal of medicinal chemistry.

[7]  R. Bansal,et al.  Pyridazin-3(2H)-ones: the versatile pharmacophore of medicinal significance , 2013, Medicinal Chemistry Research.

[8]  X. Wan,et al.  Trifluoroacetic acid catalyzed dibenzodiazocine synthesis: optimization and mechanism study , 2012 .

[9]  Kenneth A Jacobson,et al.  Recent developments in adenosine receptor ligands and their potential as novel drugs. , 2011, Biochimica et biophysica acta.

[10]  S. Moro,et al.  The identification of the 2-phenylphthalazin-1(2H)-one scaffold as a new decorable core skeleton for the design of potent and selective human A3 adenosine receptor antagonists. , 2011, Journal of medicinal chemistry.

[11]  B. Fredholm,et al.  International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors—An Update , 2011, Pharmacological Reviews.

[12]  Matthew E Welsch,et al.  Privileged scaffolds for library design and drug discovery. , 2010, Current opinion in chemical biology.

[13]  Suzanne Skolnik,et al.  Recent Advances in Physicochemical and ADMET Profiling in Drug Discovery , 2009, Chemistry & biodiversity.

[14]  S. Moro,et al.  Pyrido[2,3-e]-1,2,4-triazolo[4,3-a]pyrazin-1-one as a new scaffold to develop potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies. , 2009, Journal of medicinal chemistry.

[15]  P. Sexton,et al.  2-aminothienopyridazines as novel adenosine A1 receptor allosteric modulators and antagonists. , 2008, Journal of medicinal chemistry.

[16]  A. Lawrence,et al.  Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives. , 2008, Bioorganic & medicinal chemistry letters.

[17]  S. Gessi,et al.  Adenosine receptor antagonists: translating medicinal chemistry and pharmacology into clinical utility. , 2008, Chemical reviews.

[18]  S. Moro,et al.  Scouting human A3 adenosine receptor antagonist binding mode using a molecular simplification approach: from triazoloquinoxaline to a pyrimidine skeleton as a key study. , 2007, Journal of medicinal chemistry.

[19]  S. Moro,et al.  4-amido-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-ones as new potent and selective human A3 adenosine receptor antagonists. synthesis, pharmacological evaluation, and ligand-receptor modeling studies. , 2006, Journal of medicinal chemistry.

[20]  S. Moro,et al.  1,2,4-Triazolo[1,5-a]quinoxaline as a Versatile Tool for the Design of Selective Human A3 Adenosine Receptor Antagonists: Synthesis, Biological Evaluation, and Molecular Modeling Studies of 2-(Hetero)aryl- and 2-Carboxy-Substitued Derivatives , 2005 .

[21]  S. Nishimura,et al.  Synthesis and evaluation of [11C]FR194921 as a nonxanthine-type PET tracer for adenosine A1 receptors in the brain. , 2005, Nuclear medicine and biology.

[22]  F. Mongin,et al.  Metallation of pyridines and quinolines in the presence of a remote carboxylate group. New syntheses of heterocyclic quinones. , 2004, Organic & biomolecular chemistry.

[23]  B. Fredholm,et al.  International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. , 2001, Pharmacological reviews.

[24]  G. Giannaccini,et al.  Structure-activity relationships in a series of 8-substituted xanthines as A1-adenosine receptor antagonists. , 2001, Bioorganic & medicinal chemistry.

[25]  P. Selzer,et al.  Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. , 2000, Journal of medicinal chemistry.

[26]  C. Martini,et al.  Synthesis and structure-activity relationships of a new set of 2-arylpyrazolo[3,4-c]quinoline derivatives as adenosine receptor antagonists. , 2000, Journal of medicinal chemistry.

[27]  G Burnstock,et al.  Receptors for purines and pyrimidines. , 1998, Pharmacological reviews.

[28]  G. Giannaccini,et al.  Adenosine receptors: synthesis, structure-activity relationships and biological activity of new 6-amino purine derivatives , 1998 .

[29]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[30]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[31]  K. Jacobson,et al.  G protein-dependent activation of phospholipase C by adenosine A3 receptors in rat brain. , 1995, Molecular pharmacology.

[32]  K. Varani,et al.  Pyrazolo[1,5-c]quinazoline derivatives and their simplified analogues as adenosine receptor antagonists: synthesis, structure-affinity relationships and molecular modeling studies. , 2013, Bioorganic & medicinal chemistry.